Artificial Intelligence (AI) and Automated Decision Making (ADM) are buzzwords that are making headlines more and more frequently and have increasing influence in the healthcare space. Although implementing AI/ADM promises to streamline processes and optimise efficiencies and outcomes, greater adoption of these technologies may mean that underlying biases in data used in machine learning are reinforced and in some cases, amplified. When it comes to access to medicines, this could have far reaching consequences for our world’s already marginalised communities. 

In 2021, Health Action International were among 16 civil society organisations who received targeted core funding from the European Artificial Intelligence (AI) fund so that we can address this challenge. We aim to strengthen the existing medicines policy expertise by recognising, understanding, and reflecting on the impact of AI/ADM in our research, advocacy, and communications activities. 

In the context of this programme, we are undertaking training on the impact of AI in healthcare while mapping and engaging with relevant experts and organisations in the field. We are conducting research into AI/ADM’s application in clinical trials design, conduct and interpretation, and its impact on Health Technology Assessment processes.  

We are working closely with partners within the European Parliament and European Medicines Agency in order to disseminate our research findings, coordinate advocacy and help to drive a movement.  

We are excited to be part of this emerging and important public debate in order to represent and protect public interests so that we can continue to improve access to medicines for everyone, everywhere.